Baird analyst Eric Coldwell believes Syneos Health shares "should be down" following management's "lacking" handling of the news that its CFO is leaving about 2.5 months ahead of schedule and that the CAO has also resigned. However, he thinks the stock has fallen too far, as at the current price the market is assigning a below-average CRO multiple for its Clinical segment and "zero value" for its Commercial business, he tells investors. Coldwell, who called today's weakness "way overdone," keeps an Outperform rating and $50 price target on Syneos shares and added the stock as a short-term "Fresh Pick."